Share Name Share Symbol Market Type Share ISIN Share Description
Reneuron Group Plc LSE:RENE London Ordinary Share GB00BF5G6K95 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  6.00 5.11% 123.50 122.00 125.00 127.00 117.50 117.50 137,962 15:51:42
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 6.1 -13.9 -35.9 - 70

Reneuron Share Discussion Threads

Showing 7876 to 7895 of 8350 messages
Chat Pages: Latest  322  321  320  319  318  317  316  315  314  313  312  311  Older
They started some action with the exosomes back at the beginning of 2019: but it seems to have gone nowhere. No use having assets sitting on the shelf gathering dust - if they can't be used they should be sold for whatever they can get, with a payback on future royalties.
All the Evox post reminded me was ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces the appointment of Nicholas Adams in the newly created role of VP Business Development & Alliance Management. That was July 2019. Where's the beef?
What was the point of posting that?
What's the point of posting all that here?
Deals still being done... Evox Therapeutics and Takeda Sign Multi-target Rare Disease Collaboration Collaboration focuses on developing novel protein replacement and mRNA therapies and explores the targeted delivery of these payloads using Evox's proprietary exosome technology Partnership encompasses up to five rare disease targets, including Evox's Niemann-Pick Type C programme, with Takeda assuming responsibility for its clinical development OXFORD, England, March 26, 2020 /PRNewswire/ -- Evox Therapeutics Ltd ('Evox' or the 'Company'), a leading exosome therapeutics company, is pleased to announce the signing of a rare disease-focused partnership with Takeda Pharmaceutical Company Limited ("Takeda"). The multi-target collaboration is focussed on developing up to five novel protein replacement and mRNA therapies, including Evox's preclinical programme in Niemann-Pick disease type C (NPC) and a second new programme directed at another undisclosed rare disease. As part of the deal, Takeda also has the option to select up to three additional rare disease targets. Dr. Antonin de Fougerolles, Chief Executive Officer of Evox, commented: "We are delighted to have entered into this strategically important, multi-target partnership with Takeda, a recognised leader in the development of treatments for rare diseases. We look forward to working with Takeda to advance these exosome drugs towards the clinic. Additionally, the deal significantly extends our cash runway into late 2022 and allows us to aggressively expand our own proprietary pipeline of rare disease drugs, including a urea cycle disorder programme we expect to enter the clinic in 2021." The partnership with Takeda enables Evox to continue advancing its proprietary exosome-based targeting and delivery technology, while also leveraging Takeda's extensive development and clinical expertise to advance these partnered programmes into the clinic. Madhu Natarajan, Head of the Rare Diseases Drug Discovery Unit at Takeda, commented: "Evox Therapeutics has developed a novel approach toward treating devastating diseases, such as Niemann-Pick Type C. The targeted and non-targeted exosomes offer a highly differentiated platform with the potential to enhance tissue delivery for a variety of payloads like mRNA and proteins. Collaborating on the Evox exosome platform also complements our expanding capabilities in cell and gene therapies, particularly with the potential to develop new delivery approaches in addition to our cutting-edge adeno associated virus platform, to provide transformative therapies or functional cures for people living with rare diseases." Under the terms of the agreement, Evox will be eligible to receive up to $44 million in upfront, near-term milestone payments and research funding. In total, Evox is eligible to receive approximately $882 million in upfront, development, and commercial milestone payments from Takeda. Evox will also receive tiered royalties on net sales of each product. Evox will be primarily responsible for research and development activities for each programme until IND-enabling studies and for manufacturing up to and including Phase 1 clinical trials. Takeda will reimburse Evox for manufacturing costs incurred after the pre-clinical handover of the programmes. About Evox Therapeutics Evox Therapeutics is a privately held, Oxford-based biotechnology company focused on harnessing and engineering the natural delivery capabilities of extracellular vesicles, known as exosomes, to develop an entirely new class of therapeutics. Backed by leading life sciences venture capital groups and supported by a comprehensive intellectual property portfolio, Evox's mission is to positively impact human health by creating novel exosome-based therapeutics for the treatment of various severe diseases with limited options for patients and their families. Evox has created substantial proprietary technology to modify exosomes using various molecular engineering, drug loading, and targeting strategies to facilitate targeted drug delivery to organs of interest, including the brain and the central nervous system. Exosome-based drugs have the potential to address some of the limitations of protein, antibody and nucleic acid-based therapies by enabling delivery to cells and tissues that are currently out of reach using other drug delivery technologies, and Evox is leading the development within this emerging therapeutic space.
"but do those who live for that have anything else to live for? " My point exactly...
napoleon 14th
napoleon, If you read it again, the key words are "take no notice of this". Just follow the advice and then pay no time worrying about what the market or your shares are doing. No need to check your shares' prices. Just get on with your life.
You just have no idea these days when stuff will rise or not. If no news, very random sudden rise
Are they due results on trial?
No news. Is that the good news? I'm also wondering what that trade was doing at 128p.
Tile, you forgot to preface your comment with’Hello, hello, hello’!
What's with the large trade reported at 128
Back to the level it was at after the announcement of the first good results of the RP trial and about £1.50 down from where they tied up the Fosun deal. The shares are now valued at circa £25mil, a fairly small percentage of that deal's value.
KoP202 "When there is a stock-market boom, and everyone is scrambling for common stocks, take all your common stocks and sell them. Take the proceeds and buy conservative bonds. No doubt the stocks you sold will go higher. Pay no attention to this-just wait for the depression which will come sooner or later. When this depression-or panic-becomes a national catastrophe, sell out the bonds (perhaps at a loss) and buy back the stocks. No doubt the stocks will go still lower. Again pay no attention. Wait for the next boom. Continue to repeat this operation as long as you live, and you’ll have the pleasure of dying rich." Fred Schwed Jnr 1940 Substitute cash for bonds and recession for depression. He'd just lived through The Great Depression.
anybody seen raytard
anybody seen raytard another beauty boom
anybody seen raytard another beauty
I have added yesterday and today. My only concern is that the company will need to raise cash at some point. However, if RP results are good in six months it should not have any trouble raising funds. napoleon - if the market is looking for a treatment for the virus it should look at Synairgen SNG which is waiting on antiviral trial results.
Fed up? Just remember that the Chairman bought 80,000 at £2.15 less than a year ago and has since gone from an over £80,000 profit to an over £80,000 loss. I can't imagine that the recent acquirers of 16% of the company are too chuffed either. The economic impact of this virus has produced two negatives: if you didn't have plenty of cash to tide you over a lengthy period of very poor trading you either need a VERY friendly bank or you are in big trouble; second, if your pension fund was in substantial deficit before, it has a much bigger one now as yields (the discount rate on liabilities) have dropped significantly.
Chat Pages: Latest  322  321  320  319  318  317  316  315  314  313  312  311  Older
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210618 16:06:51